Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Efficacy, Safety and Tolerability Study of ALKS 3831 in Schizophrenia With Alcohol Use Disorder

NCT02161718 is registered in ClinicalTrials.gov with Alkermes, Inc. as lead sponsor.

NCT NCT02161718
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02161718 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Efficacy, Safety and Tolerability Study of ALKS 3831 in Schizophrenia With Alcohol Use Disorder
Lead sponsor
Alkermes, Inc.
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2014
Completion date
February 1, 2017
Enrollment
300 (actual)
Sites
71

Conditions

As the registry lists them; a condition with its own page is linked.

alcohol use disorder, schizophrenia